A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido lung cancer clinical study group trial (HOT) 0901

Oncologist

Volumn 18, Issue 4, 2013, Pages 439-445

  Harada, Toshiyuki ^a   Oizumi, Satoshi ^b   Ito, Kenichiro ^c   Takamura, Kei ^c   Kikuchi, Eiki ^b   Kuda, Tomoya ^d   Sugawara, Shunichi ^d   Suzuki, Aya ^e   Maemondo, Makoto ^e   Fujita, Yuka ^f   Kinoshita, Ichiro ^g   Inoue, Akira ^h   Hommura, Fumihiro ⁱ   Katsuura, Yutaka ^j   Dosaka Akita, Hirotoshi ^g   Isobe, Hiroshi ^k   Nishimura, Masaharu ^b  

^a Hokkaido Social Insurance Hospital   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c Obihiro Kousei Hospital   (Japan)

^d SENDAI KOUSEI HOSPITAL   (Japan)

^e Miyagi Cancer Center   (Japan)

^f National Hospital Organization Asahikawa Medical Center   (Japan)

^g HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h TOHOKU UNIVERSITY HOSPITAL   (Japan)

ⁱ SAPPORO CITY GENERAL HOSPITAL   (Japan)

^j Saiseikai Fukushima General Hospital   (Japan)

^k Sapporo Medical University   (Japan)

more..

Author keywords

Amrubicin; Chemotherapy; Fourth line; Non small cell lung cancer; Third line

Indexed keywords

AMRUBICIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LIVER FAILURE; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTHRACYCLINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 84877041134     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0308     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Pfister DG, Johnson DH, Azzoli CG et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable nonsmall- cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-353.
3. Schiller JH, Harrington D, Belani CP et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmall- cell lung cancer. N Engl J Med 2002;346:92-98.
4. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival inadvancednon-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
5. Oizumi S, Kobayashi K, Inoue A et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of North East Japan Study Group 002 Trial. The Oncologist 2012;17:863-887.
6. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005;353:123-132.
8. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
9. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
10. Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. The Oncologist 2006;11:1095-1099.
11. Asahina H, Sekine I, Horinouchi H et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012;13:39-43.
12. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. The Oncologist 2008; 13(suppl 1):14-20.
13. Azzoli CG, Baker S Jr, Temin S et al.; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
14. Girard N, Jacoulet P, GainetMet al. Third-line chemotherapy in advanced non-small cell lung cancer: Identifying the candidates for routine practice. J Thorac Oncol 2009;4:1544-1549.
15. Hanada M, Mizuno S, Fukushima A et al.Anew antitumoragentamrubicin induces cellgrowthinhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89:1229-1238.
16. Inoue A, Sugawara S, Yamazaki K et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated smallcell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
17. Sawa T, Yana T, Takada M et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 2006; 24:151-158.
18. Okamoto I, Hamada A, Matsunaga Y et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. CancerChemother Pharmacol 2006;57:282-288.
19. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
21. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non- Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
22. Takeda K, Takifuji N, Negoro S et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: A West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:377-383.
23. Kaneda H, Okamoto I, Hayashi H et al. West JapanThoracic Oncology Group. Phase II trial of amrubicin for second-line treatment of advanced nonsmall cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG0401). J Thorac Oncol 2010;5:105-109.
24. Kaira K, Sunaga N, Tomizawa Y et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2010;69:99-104.
25. Igawa S, Takahashi T, Nakamura Y et al. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens. Anticancer Res 2008;28:3855-3858.
26. Song Z, Yu Y, Chen Z et al. Third-line therapy for advanced non-small-cell lung cancer patients: Feasible drugs for feasible patients. Med Oncol 2011; 28(suppl 1):S605-S612.
27. Hotta K, Fujiwara Y, Kiura K et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2007;2:402-407.
28. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26: 4244-4252.
29. Ohe Y, Ichinose Y, Nakagawa K et al. Efficacy and safety of two doses of pemetrexed supplementedwith folic acidandvitaminB12in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-4212.